DGAP-News: Proteo, Inc. / Proteo Biotech AG: FDA grants Proteo Orphan Drug Designation to Elafin for the treatment of pulmonary arterial hypertension
DGAP-News: Proteo Biotech AG / Schlagwort(e):
Sonstiges/Zwischenbericht
Proteo, Inc. / Proteo Biotech AG: FDA grants Proteo Orphan Drug
Designation to Elafin for the treatment of pulmonary arterial
hypertension
10.01.2013 / 11:30
———————————————————————
Proteo, Inc. / Proteo Biotech AG: FDA grants Proteo Orphan Drug Designation
to Elafin for the treatment of pulmonary arterial hypertension
Irvine, CA – Kiel, January 10, 2013 – Proteo, Inc. (OTCQB
